Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.

Area of Science:

• Dermatology
• Clinical Medicine
• Health Outcomes Research

Background:

• Limited real-world data exists on the burden of hidradenitis suppurativa (HS).
• Understanding the impact of HS on patients' daily lives is crucial for effective treatment strategies.

Purpose of the Study:

• To evaluate the effect of adalimumab on health-related quality of life (HRQoL) in moderate-to-severe HS patients.
• To assess the impact of adalimumab on work productivity and daily activity impairment in HS patients.

Main Methods:

• A real-world study involving 138 adults with moderate-to-severe HS across 23 Canadian centers.
• Patients received adalimumab for up to 52 weeks, with outcomes assessed using patient-reported outcome measures (PROMs) at baseline, week 24, and week 52.
• PROMs included measures of HRQoL, HS severity, anxiety, depression, and work productivity; a post-hoc analysis examined outcomes based on abscess and inflammatory nodule (AN) counts.

Main Results:

• Significant improvements in overall HRQoL and HS symptom scores were observed from baseline to weeks 24 and 52 (P ≤ .0023).
• Patient-reported "good disease control" increased from 9.7% to 66.4% over 52 weeks, with meaningful pain reduction (HUI3).
• Work productivity loss and activity impairment improved by approximately 20%, with greater benefits seen in patients with lower baseline AN counts.

Conclusions:

• Adalimumab demonstrated a meaningful improvement in HRQoL and work productivity for moderate-to-severe HS patients in a real-world setting.
• These improvements were evident by week 24 and sustained through week 52.
• The study highlights adalimumab's efficacy in reducing the disease burden and improving daily functioning for individuals with HS.